Drug Trial Radar · NCT06873555
A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Sep 11, 2024
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Heronova PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Mar 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, open-label, cohort expansion Phase Ib/IIa trial designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profile of DC05F01 in patients with recurrent/refractory ovarian cancer and other advanced solid tumors.
Conditions
- Solid Tumors
- Ovarian Cancer
- Small Cell Lung Cancer
Interventions
DC05F01Drug
DC05F01 capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (ORR)Time frame: Up to 24 months
- Progression-free Survival (PFS)Time frame: Up to 24 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The Fisrt Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.